Carbamazepine-viloxazine interaction in patients with epilepsy

F. Pisani, A. Fazio, G. Oteri, E. Perucca, M. Russo, R. Trio, B. Pisani, R. Di Perri

Research output: Contribution to journalArticlepeer-review


In six depressed epileptic patients stabilised on carbamazepine therapy, addition of the antidepressant agent viloxazine (300 mg/day for three weeks) induced a marked (average 55%) increase in steady-state plasma carbamazepine concentration. The concentration of the active metabolite carbamazepine-10,11 -epoxide also increased during viloxazine therapy, but to a lesser extent (16%). In three patients, these effects were associated with symptoms of carbamazepine intoxication, which regressed rapidly when plasma carbamazepine and carbamazepine-10,11- epoxide levels returned to baseline values after discontinuation of viloxazine. In a seventh patient, viloxazine had to be discontinued after only two weeks because of severe side effects associated with a striking elevation of carbamazepine and carbamazepine 10,11 -epoxide levels (by 197% and 137% respectively). Although viloxazine appears to be one of the few antidepressants which can be used safely in patients with epilepsy these results indicate that the drug should be prescribed with great caution in subjects treated with carbamazepine. The mechanism of the interaction probably involves inhibition of the metabolism of both carbamazepine and its active epoxide metabolite.

Original languageEnglish
Pages (from-to)1142-1145
Number of pages4
JournalJournal of Neurology, Neurosurgery and Psychiatry
Issue number10
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health


Dive into the research topics of 'Carbamazepine-viloxazine interaction in patients with epilepsy'. Together they form a unique fingerprint.

Cite this